Literature DB >> 30903736

The neonatal Fc receptor: Key to homeostasic control of IgG and IgG-related biopharmaceuticals.

William M Baldwin1, Anna Valujskikh1, Robert L Fairchild1.   

Abstract

IgG and albumin are the most abundant proteins in the circulation and have the longest half-lives. These properties are due to a unique receptor, the neonatal Fc receptor (FcRn). Although FcRn is named for its function of transferring IgG across the placenta from maternal to fetal circulation, FcRn functions throughout life to maintain IgG and albumin concentrations. FcRn protects IgG and albumin from intracellular degradation and recycles them back into the circulation. Clinical trials have confirmed that pathogenic antibodies can be depleted by blocking this homeostatic function of FcRn. Moreover, understanding the molecular interactions between IgG and FcRn has resulted in the design of therapeutic monoclonal antibodies with more efficacious pharmacokinetics. As a result of genetic engineering these monoclonals can be delivered at lower doses and at longer intervals. More recent findings have demonstrated that FcRn enhances phagocytosis by neutrophils, immune complex clearance by podocytes and antigen presentation by dendritic cells, macrophages, and B cells. This minireview highlights the relevance of FcRn to transplantation.
© 2019 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  alloantibody; bioengineering; cellular biology; immune regulation; immunobiology; immunosuppressant - fusion proteins and monoclonal antibodies; immunosuppression/immune modulation; sensitization; translational research/science

Year:  2019        PMID: 30903736      PMCID: PMC6591018          DOI: 10.1111/ajt.15366

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  47 in total

Review 1.  Engineered antibodies.

Authors:  Peter J Hudson; Christelle Souriau
Journal:  Nat Med       Date:  2003-01       Impact factor: 53.440

2.  A THEORETICAL MODEL OF GAMMA-GLOBULIN CATABOLISM.

Authors:  F W BRAMBELL; W A HEMMINGS; I G MORRIS
Journal:  Nature       Date:  1964-09-26       Impact factor: 49.962

3.  The hydrolysis of rabbit y-globulin and antibodies with crystalline papain.

Authors:  R R PORTER
Journal:  Biochem J       Date:  1959-09       Impact factor: 3.857

4.  Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels.

Authors:  Carlos Vaccaro; Jinchun Zhou; Raimund J Ober; E Sally Ward
Journal:  Nat Biotechnol       Date:  2005-09-25       Impact factor: 54.908

5.  FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis.

Authors:  Gestur Vidarsson; Annette M Stemerding; Nigel M Stapleton; Suzanne E Spliethoff; Hans Janssen; Frank E Rebers; Masja de Haas; Jan G van de Winkel
Journal:  Blood       Date:  2006-07-18       Impact factor: 22.113

6.  A variable number of tandem repeats polymorphism influences the transcriptional activity of the neonatal Fc receptor alpha-chain promoter.

Authors:  Ulrich J H Sachs; Ines Socher; Christian G Braeunlich; Hartmut Kroll; Gregor Bein; Sentot Santoso
Journal:  Immunology       Date:  2006-06-23       Impact factor: 7.397

7.  Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases.

Authors:  Ning Li; Minglang Zhao; Julio Hilario-Vargas; Phillip Prisayanh; Simon Warren; Luis A Diaz; Derry C Roopenian; Zhi Liu
Journal:  J Clin Invest       Date:  2005-11-10       Impact factor: 14.808

8.  Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade.

Authors:  Liming Liu; Ana Maria Garcia; Helen Santoro; Yixia Zhang; Kevin McDonnell; Jennifer Dumont; Alan Bitonti
Journal:  J Immunol       Date:  2007-04-15       Impact factor: 5.422

9.  Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism.

Authors:  Shreeram Akilesh; Gregory J Christianson; Derry C Roopenian; Andrey S Shaw
Journal:  J Immunol       Date:  2007-10-01       Impact factor: 5.422

10.  Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn.

Authors:  Adam R Mezo; Kevin A McDonnell; Cristina A Tan Hehir; Susan C Low; Vito J Palombella; James M Stattel; George D Kamphaus; Cara Fraley; Yixia Zhang; Jennifer A Dumont; Alan J Bitonti
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-12       Impact factor: 11.205

View more
  5 in total

Review 1.  Research progress on neonatal Fc receptor and its application.

Authors:  Mangsha Hu; Shuli Wei; Wuyuan Zhou; Pingli Wang
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-08-25

2.  The Pharmacogenetics of Rituximab: Potential Implications for Anti-CD20 Therapies in Multiple Sclerosis.

Authors:  Michael Zhong; Anneke van der Walt; Maria Pia Campagna; Jim Stankovich; Helmut Butzkueven; Vilija Jokubaitis
Journal:  Neurotherapeutics       Date:  2020-10-14       Impact factor: 7.620

Review 3.  Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology.

Authors:  Etienne Chatelut; Jeroen J M A Hendrikx; Jennifer Martin; Joseph Ciccolini; Dirk Jan A R Moes
Journal:  Pharmacol Res Perspect       Date:  2021-04

4.  No evidence for hypogammaglobulinemia in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with ravulizumab.

Authors:  Ferras Alashkar; Scott Rottinghaus; Colin Vance; Dörte Herich-Terhürne; Ulrich Dührsen; Roland Assert; Alexander Röth
Journal:  PLoS One       Date:  2020-03-27       Impact factor: 3.240

5.  Measuring the Impact of Targeting FcRn-Mediated IgG Recycling on Donor-Specific Alloantibodies in a Sensitized NHP Model.

Authors:  Miriam Manook; Walter J Flores; Robin Schmitz; Zachary Fitch; Janghoon Yoon; Yeeun Bae; Brian Shaw; Allan Kirk; Melissa Harnois; Sallie Permar; Alton B Farris; Diogo M Magnani; Jean Kwun; Stuart Knechtle
Journal:  Front Immunol       Date:  2021-06-02       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.